We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Angle Plc | LSE:AGL | London | Ordinary Share | GB0034330679 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
4.00 | 29.09% | 17.75 | 17.00 | 18.50 | 18.25 | 15.25 | 16.25 | 7,554,983 | 16:29:58 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Business Services, Nec | 1.04M | -21.69M | -0.0832 | -2.13 | 46.25M |
TIDMAGL
Angle PLC
02 August 2016
London, UK, 2 August 2016
Edison issues ADR update on Angle (ANPCY)
Recent newsflow from Angle and the FY16 report released last week showed progress in developing and commercializing the liquid biopsy diagnostic system Parsortix. The R&D strategy is progressing, with the ovarian cancer trials recruiting first patients in the US and Europe and on track to deliver data around end-2016, while the first research use sales met our expectations and a new large client is on board. Our updated valuation of Angle is $171m (vs $136m previously).
We have revised our valuation of Angle and now include metastatic breast cancer and prostate cancer applications in addition to our previous DCF-based valuation of Angle's core operations and ovarian cancer application. We calculate the two new applications add $20m to Angle's valuation. Following strong news flow in recent months, ramp-up of R&D activities and initial sales meeting our expectations, we increase our valuation to $171m (from $136m) or $23/ADR.
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com
About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
Contact details: Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn www.linkedin.com/company/edison-investment-research --------- ---------------------------------------------------- Twitter www.twitter.com/Edison_Inv_Res --------- ---------------------------------------------------- YouTube www.youtube.com/edisonitv --------- ---------------------------------------------------- Google+ https://plus.google.com/105425025202328783163/posts --------- ----------------------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAAKBDNQBKDDFK
(END) Dow Jones Newswires
August 02, 2016 10:37 ET (14:37 GMT)
1 Year Angle Chart |
1 Month Angle Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions